|
End-of-day quote
Shanghai S.E.
18/09/2026
|
5-day change | 1st Jan Change | ||
| 6.610 CNY | +0.15% |
|
-0.30% | +1.85% |
| Market Cap | 4.57B 683M 595M 562M 510M 956M 65.49B 960M 6.73B 2.6B 33.3B 2.56B 2.51B 107B | P/E 2024 |
18.1x | P/E 2025 | 14.2x |
|---|---|---|---|---|---|
| Enterprise Value | 3.79B 565M 493M 466M 423M 792M 54.26B 795M 5.58B 2.15B 27.59B 2.12B 2.08B 88.76B | EV / Sales 2024 |
1.45x | EV / Sales 2025 | 1.65x |
| Free-Float |
79.74% | Yield 2024 |
4.93% | Yield 2025 | 5.39% |
| 1 day | +0.15% | ||
| 1 week | -0.30% | ||
| Current month | -7.16% | ||
| 1 month | -6.77% | ||
| 3 months | +10.54% | ||
| 6 months | -0.45% | ||
| Current year | +1.85% |
| 1 week | 6.5 |  | 6.79 |
| 1 month | 6.5 | | 7.33 |
| Current year | 5.6 | | 7.45 |
| 1 year | 5.6 | | 7.45 |
| 3 years | 4.94 | | 9 |
| 5 years | 4.94 | | 11.9 |
| 10 years | 4.5 | | 11.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wei Ren
CEO | Chief Executive Officer | 42 | 23/04/2019 |
Zhe Feng Zuo
DFI | Director of Finance/CFO | 54 | 17/05/2017 |
Peng Bo Ren
PRN | Corporate Officer/Principal | 53 | 11/03/2007 |
| Director | Title | Age | Since |
|---|---|---|---|
Wu Xian Ren
CHM | Chairman | 66 | 26/05/2005 |
Peng Bo Ren
BRD | Director/Board Member | 53 | 15/05/2014 |
Wei Ren
BRD | Director/Board Member | 42 | 23/04/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.15% | -0.30% | -1.64% | -20.74% | 683M | |
| -1.61% | -0.15% | +11.45% | +60.09% | 45.94B | |
| -1.02% | -1.90% | +35.99% | +100.50% | 37.22B | |
| +2.19% | +3.65% | +10.70% | +80.29% | 12.06B | |
| +1.32% | +2.09% | -11.64% | +12.41% | 11.74B | |
| -0.95% | 0.00% | +18.72% | +150.00% | 9.03B | |
| +0.39% | +2.39% | +29.99% | +38.63% | 7.36B | |
| -0.06% | +2.97% | +38.90% | -18.67% | 7.15B | |
| +1.30% | +1.17% | +16.08% | +187.41% | 7.2B | |
| +0.70% | +1.10% | -44.22% | +5.78% | 5.03B | |
| Average | +0.24% | +0.76% | +10.43% | +59.57% | 14.34B | |
| Weighted average by Cap. | -0.44% | +0.21% | +16.86% | +73.11% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 2.69B 401M 349M 330M 300M 561M 38.46B 564M 3.95B 1.53B 19.55B 1.51B 1.47B 62.91B | 2.24B 334M 291M 275M 250M 468M 32.07B 470M 3.3B 1.27B 16.31B 1.26B 1.23B 52.47B |
| Net income | 243M 36.21M 31.58M 29.82M 27.08M 50.73M 3.47B 50.94M 357M 138M 1.77B 136M 133M 5.68B | 320M 47.75M 41.64M 39.32M 35.7M 66.89M 4.58B 67.17M 471M 182M 2.33B 179M 175M 7.5B |
| Net Debt | -483M -72.05M -62.83M -59.33M -53.87M -101M -6.91B -101M -711M -274M -3.52B -271M -265M -11.31B | -784M -117M -102M -96.36M -87.51M -164M -11.23B -165M -1.15B -445M -5.71B -440M -430M -18.37B |
Employees
3,415
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/09/26 | CNY 6.610 | +0.15% | 16,252,000 |
| 17/09/26 | CNY 6.600 | -0.15% | 10,187,286 |
| 16/09/26 | CNY 6.610 | -0.15% | 13,676,104 |
| 15/09/26 | CNY 6.620 | -2.07% | 17,359,822 |
| 14/09/26 | CNY 6.760 | +1.96% | 19,991,200 |
- Stock Market
- Stocks
- 600351 Stock
Select your edition
All financial news and data tailored to specific country editions
